Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Akero Therapeutics, Inc. (AKRO : NSDQ)
 
 • Company Description   
Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which are in clinical stage. Akero Therapeutics Inc. is based in San Francisco, United States.

Number of Employees: 22

 
 • Price / Volume Information   
Yesterday's Closing Price: $19.90 Daily Weekly Monthly
20 Day Moving Average: 213,559 shares
Shares Outstanding: 34.89 (millions)
Market Capitalization: $694.27 (millions)
Beta: 0.51
52 Week High: $34.87
52 Week Low: $17.66
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -22.45% -20.03%
12 Week -19.24% -20.04%
Year To Date -22.87% -35.02%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
601 GATEWAY BOULEVARD SUITE 350
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 650-487-6488
fax: -
ir@akerotx.com http://www.akerotx.com
 
 • General Corporate Information   
Officers
Andrew Cheng - Chief Executive Officer; President and Director
William White - Executive Vice President; Chief Financial Officer
Kevin Bitterman - Director
Seth L. Harrison - Director
Jane P. Henderson - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00973Y108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 03/15/22
Share - Related Items
Shares Outstanding: 34.89
Most Recent Split Date: (:1)
Beta: 0.51
Market Capitalization: $694.27 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.83 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.74 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.50
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -11.11%
vs. Previous Quarter: 15.66%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
09/30/21 - -42.47
06/30/21 - -37.63
03/31/21 - -36.84
ROA
09/30/21 - -39.52
06/30/21 - -35.60
03/31/21 - -34.88
Current Ratio
09/30/21 - 9.42
06/30/21 - 14.35
03/31/21 - 25.23
Quick Ratio
09/30/21 - 9.42
06/30/21 - 14.35
03/31/21 - 25.23
Operating Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Net Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Pre-Tax Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Book Value
09/30/21 - 5.69
06/30/21 - 6.32
03/31/21 - 7.07
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - 0.00
06/30/21 - 0.00
03/31/21 - 0.00
Debt-to-Capital
09/30/21 - 0.00
06/30/21 - 0.00
03/31/21 - 0.00
 

Powered by Zacks Investment Research ©